3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Other hematologic neoplasm
2
CNS
2
Thoracic
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
pembrolizumab
161
Nivolumab
133
Ipilimumab
78
Cyclophosphamide
47
Specimen Handling
44
Magnetic Resonance Spectroscopy
39
cemiplimab
35
Biopsy
31
fludarabine
29
trametinib
24
relatlimab
24
binimetinib
23
Interleukin-2
22
fludarabine phosphate
21
dabrafenib
20
atezolizumab
20
Radiotherapy
20
Opdualag
19
aldesleukin
18
Radiosurgery
18
CTLA-4 Antigen
18
encorafenib
17
Blood Specimen Collection
17
avelumab
14
Immunoglobulin G
14
Disulfides
13
lifileucel
11
lenvatinib
11
Bevacizumab
11
Paclitaxel
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interleukin-15
×
Dermatologic
×
1 year
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled